AngioDynamics, Inc. announced its financial results for the second quarter of fiscal year 2026, ending November 30, 2025.
The company experienced continued double-digit growth in its Med Tech segment, strong adjusted EBITDA, and positive cash flow.
Key regulatory milestones were achieved, supporting the Mechanical Thrombectomy portfolio.
The strong financial performance was driven by strategic advancements in product development and regulatory approvals.
Double-Digit Growth
The Med Tech segment achieved its fifth consecutive quarter of double-digit growth, showcasing the company's ability to capture market share and drive revenue growth through innovation.
Regulatory Milestones
AngioDynamics received critical FDA approvals, including FDA IDE approvals for the APEX-Return study and PAVE clinical study, along with FDA 510(k) clearance for the modified AlphaVac F1885 System. These milestones highlight the company's commitment to compliance and product enhancement, positioning it favorably for market expansion.
Guidance Increase
By raising its full-year FY 2026 guidance for net sales and Adjusted EBITDA, AngioDynamics signals confidence in its continued growth trajectory and operational efficiency, indicating strong market positioning and strategic planning.
- AngioDynamics achieved a substantial increase in net sales during the second quarter of fiscal year 2026, reporting a noteworthy growth rate of 8.8% compared to the same period in the previous year.
- The Med Tech segment exhibited robust performance, with significant sales growth observed in key product lines such as Auryon, Mechanical Thrombectomy, and NanoKnife, reflecting the company's successful product innovation and market penetration strategies.
- The successful acquisition of FDA approvals and clearances underscores AngioDynamics' strategic focus on technological advancement and regulatory compliance, reinforcing its competitive edge in the evolving medical technology landscape and enhancing investor confidence in the company's growth prospects.
With a stellar performance in the second quarter of fiscal year 2026, driven by robust revenue growth and strategic regulatory achievements, AngioDynamics is well-positioned for sustained expansion and innovation in the highly competitive medical technology sector, demonstrating resilience and adaptability in a dynamic market environment.